Table 4. Univariate and multivariate regression analyses of survival and recurrence in patients with NSCLC.

Factor	Overall survival								Progression-free survival
	Univariate				Multivariate				Univariate			Multivariate
	HR	95% CI	P		HR	95% CI	P		HR	95% CI		P	HR	95% CI	P
Gender (male vs. female)	1.177	0.580–2.388	0.652						1.145	0.616–2.127		0.669
Age (>65 vs. ≤65 years)	1.320	0.797–2.184	0.281						1.155	0.731–1.826		0.537
Complication (yea vs. no)	1.188	0.724–1.946	0.497						1.093	0.692–1.754		0.705
Smoking (>30 vs. ≤30 pack-year)	1.406	0.833–2.375	0.201						1.125	0.703–1.799		0.624
T stage (T3–4 vs. T1–2)	2.976	1.689–5.263	0.000		3.215	1.792–5.747	0.000		2.392	1.389–4.115		0.002	2.252	1.300–3.921	0.004
N stage (N2–3 vs. N0–1)	1.721	1.034–2.865	0.037						1.616	1.016–2.564		0.042
Chemotherapy (no vs. yes)	0.578	0.346–0.964	0.036						1.587	0.998–2.525		0.051
Concurrent chemoradiotherapy (no vs. yes)	1.227	0.707–2.128	0.468						1.336	0.824–2.262		0.226
Radiotherapy technology (IMRT vs. SBRT)	1.756	0.988–3.123	0.055						1.773	1.059–2.968		0.029
Target therapy (no vs. yes)	1.047	0.475–2.304	0.910						1.114	0.532–2.326		0.776
ERCC1 rs11615 A vs. G	2.105	1.271–3.484	0.004		2.451	1.435–4.184	0.001		1.623	1.018–2.591		0.042	1.497	0.932–2.404	0.095
ERCC1 rs3212961 T vs. G	1.276	0.686–2.370	0.442						1.035	0.610–1.756		0.897
ERCC1 rs3212986 A vs. C	1.554	0.936–2.581	0.088		2.538	1.149–5.618	0.021		1.206	0.763–1.905		0.423
ERCC2 rs13181 G vs. T	1.153	0.568–2.342	0.692						1.033	0.542–1.969		0.921
ERCC2 rs238406 T vs. G	1.177	0.678–2.043	0.562						1.516	0.924–2.488		0.100
ERCC2 rs1799793 T vs. C	1.585	0.752–3.333	0.226						1.342	0.664–2.717		0.413

NSCLC, non-small cell lung cancer. CI, confidence interval; IMRT, intensity modulated radiotherapy; SBRT, stereotactic body radiation therapy.